Cellectis Inc.

Good morning, everyone, and welcome to the Selectix third quarter 2023 earnings call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. Please be aware that today's conference call is being recorded. I'd now like to introduce our first speaker, Arthur Strill, Chief Business Officer. You may begin.

Good morning, and welcome everyone to Selective Third Quarter 2023 Corporate Update and Financial Results Conference Call. Joining me on the call today with prepared remarks are Dr. André Choulika, our Chief Executive Officer, Dr. Bing Wang, our Chief Financial Officer, and Dr. Mark Frittini, our Chief Medical Officer. Yesterday evening, Selectus issued a press release reporting a corporate and business update for the third quarter 2023, and its financial results for the nine-month period ended September 30th, 2023. As a reminder, we will make statements regarding Selectus' financial outlook, including the sufficiency of cash-to-fund operations, in addition to its manufacturing, regulatory, and product development status and plans, and product development of its licensed partners. These forward statements, which are based on our management's current expectations and assumptions, and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners, are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent Form 20-F filed with the Security Exchange Commission, SEC, and the financial reports, including the management report, for the year ended on December 31st, 2022, and subsequent filing selective makes with the SEC from time to time.

I would now like to turn the call over to Andre.